Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- enfortumab vedotin
- Relyvrio (sodium phenylbutyrate / taurursodiol)
Interactions between your drugs
enfortumab vedotin taurursodiol
Applies to: enfortumab vedotin, Relyvrio (sodium phenylbutyrate / taurursodiol)
Taurursodiol may alter the blood levels and effects of enfortumab vedotin. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
sodium phenylbutyrate food
Applies to: Relyvrio (sodium phenylbutyrate / taurursodiol)
Food may affect the absorption of sodium phenylbutyrate. A high-fat, high-calorie meal (approximately 800 to 1000 calories; 500 to 600 calories from fat, 250 calories from carbohydrate, 150 calories from protein) has been shown to reduce the absorption of sodium phenylbutyrate, although it is unknown what impact this may have on the overall effectiveness of the medication. The manufacturer recommends taking sodium phenylbutyrate before a meal or snack. This is especially important if you weigh less than 70 kg (approximately 154 pounds). Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medication without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Imfinzi
Imfinzi (durvalumab) is an immunotherapy used to treat types of lung cancer (NSCLC, SCLC), bile ...
Padcev
Padcev (enfortumab vedotin) is an antibody-drug conjugate that is given as an intravenous infusion ...
Platinol
Platinol is used for bladder cancer, blood cell transplantation, bone marrow transplantation, brain ...
Bavencio
Bavencio (avelumab) is a cancer medicine that interferes with the growth and spread of cancer cells ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.